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Abstract
During tumor progression, EphA2 receptor can gain ligand-independent pro-oncogenic functions due to Akt activation and
reduced ephrin-A ligand engagement. The effects can be reversed by ligand stimulation, which triggers the intrinsic tumor
suppressive signaling pathways of EphA2 including inhibition of PI3/Akt and Ras/ERK pathways. These observations argue
for development of small molecule agonists for EphA2 as potential tumor intervention agents. Through virtual screening
and cell-based assays, we report here the identification and characterization of doxazosin as a novel small molecule agonist
for EphA2 and EphA4, but not for other Eph receptors tested. NMR studies revealed extensive contacts of doxazosin with
EphA2/A4, recapitulating both hydrophobic and electrostatic interactions recently found in the EphA2/ephrin-A1 complex.
Clinically used as an a1-adrenoreceptor antagonist (CarduraH) for treating hypertension and benign prostate hyperplasia,
doxazosin activated EphA2 independent of a1-adrenoreceptor. Similar to ephrin-A1, doxazosin inhibited Akt and ERK kinase
activities in an EphA2-dependent manner. Treatment with doxazosin triggered EphA2 receptor internalization, and
suppressed haptotactic and chemotactic migration of prostate cancer, breast cancer, and glioma cells. Moreover, in an
orthotopic xenograft model, doxazosin reduced distal metastasis of human prostate cancer cells and prolonged survival in
recipient mice. To our knowledge, doxazosin is the first small molecule agonist of a receptor tyrosine kinase that is capable
of inhibiting malignant behaviors in vitro and in vivo.
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Introduction
As a member of the erythropoietin-producing hepatocellular
(Eph) subfamily of receptor tyrosine kinases (RTKs), EphA2 was
originally called epithelial cell kinase, or Eck, due to its widespread
expression in epithelial cells in vitro and in vivo [1]. Subsequent
studies revealed that EphA2 was overexpressed in human cancers,
and that overexpression was correlated with malignant progression
and poor prognosis [2], [3]. A large number of studies have
demonstrated that EphA2 overexpression and activation promote
tumorigenesis, suggesting a potential role as an oncogene [4], [5],
[6], [7], [8]. Overexpression of EphA2 in breast epithelial cells
induced morphological transformation [8], while in prostate
cancer and glioma cell lines, elevated EphA2 expression caused
increased chemotactic cell migration and invasion [9].
Contrasting the pro-oncogenic roles, many studies have shown
that EphA2 activation by its ligand, ephrin-A1, regulates cellular
behaviors in a manner more consistent with it being a tumor
suppressor, including induction of apoptosis, inhibition of cell
proliferation, and suppression of cell migration [7], [10], [11],
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[12]. In vivo studies demonstrate that EphA2 activation by
systemically administered ephrin-A1 decreases tumorigenicity
and invasiveness of carcinoma xenografts [13], [14]. Moreover,
EphA2 deletion mice show increased susceptibility to carcinogen-
induced skin tumorigenesis [15].
Recent studies are beginning to shed light on the paradoxical
observations [3], [16]. It is revealed that EphA2 receptor has
diametrically opposite roles in tumorigenesis [9]. Upon ligand
stimulation, EphA2 inhibits cell migration in keeping with the
well-established repulsive roles of Eph receptors in regulating cell
motility [17], [18]. In direct contrast, in the absence of ligand,
EphA2 promotes cell migration, which is correlated with its
expression level. Mechanistically, EphA2 is found to be a substrate
of Akt that is activated in different human cancers [9], [19]. Akt
phosphorylates EphA2 on serine 897 located in the well-exposed
loop between kinase domain and sterile-a motif (SAM). Muta-
genesis, pharmacological and cellular studies show S897 phos-
phorylation is essential for migration-stimulatory effects of the
EphA2 in the absence of ligand [9]. EphA2 overexpression is often
accompanied by loss of expression or mislocalization of ephrin-A1
in breast cancer [20], glioma [21] and skin tumors [15]. The
reduced ephrin-A expression coupled with increased EphA2
expression and frequent Akt activation provide a permissive
environment to promote ligand-independent pro-invasive Akt-
EphA2 crosstalk, which may be in part responsible for EphA2
overexpression during tumor progression and the correlation of
EphA2 expression and unfavorable prognosis. Supporting this
notion, immunohistochemical examination of human glioma
specimens with an antibody against the phospho-S897 revealed
that activation of Akt-EphA2 signaling is associated with
malignant progression [9].
Importantly, ligand stimulation of tumor cells in vitro inacti-
vates Akt and causes dephosphorylation of EphA2 on S897 [9],
pointing to the intricate dichotomy of EphA2 functions, i.e.,
ligand-dependent tumor suppression and ligand-independent
tumor promotion. Other tumor suppressor functions of EphA2
are also activated upon ligand-induced EphA2 activation,
including inactivation of the Ras/ERK pathway. The ligand-
dependent signaling culminates in the inhibition of cell migration
and proliferation, although the specific responses are modulated
by cellular context, such as Ras activation status in a given tumor
cell type. These studies motivated us to propose that small
molecule agonists for EphA2 can be exploited as novel cancer
therapeutics. As illustrated in Figure 1A, such agonists may not
only sever the pro-oncogenic Akt-EphA2 crosstalk, but also re-
activate intrinsic ligand-dependent tumor suppressor functions of
EphA2.
In this study, we have sought to identify small molecule agonists
using a combination of structure-based virtual screening and cell-
based assays. We report the discovery and characterization of
doxazosin as a novel agonist for EphA2 and EphA4. Moreover, in
a newly established orthotopic xenograft model of metastatic
prostate cancer, systemic administration of doxazosin significantly
suppressed distal metastasis and prolonged overall survival. To our
knowledge, this is the first example of a small molecule RTK
agonist with anti-cancer efficacy in vitro and in vivo.
Results
Structure-based virtual screening and cell-based assays
identifies doxazosin as an agonist capable of inducing
catalytic activation of EphA2 receptor tyrosine kinase
To identify small molecule agonists for EphA2, we took a
structure-based in silico screening approach. Our molecular
modeling of the EphA2 ligand-binding domain (LBD) based on
the crystal structure of the EphB2 LBD [22] revealed that the
binding pocket of EphA2 can incorporate up to 4 amino acids,
suggesting that it could accommodate small molecules with a
molecular weight (MW) of about 500 Dalton [23]. This notion was
confirmed recently by determination of the crystal structure of the
EphA2/ephrin-A1 complex [24] (Figure 1B). The size falls in the
range of common drugs [25], making EphA2 LBD a desirable
target for drug discovery. Toward this end, we initiated in silico
screening to search for small molecules that interact favorably with
the ligand-binding pocket of EphA2 derived from molecular
modeling [23] before the crystal structure became available.
Multiple conformations for each structure were generated with
OMEGA (OpenEye) and each conformation was docked individ-
ually using DOCK [26]. Our initial screening of over 750,000
compounds identified a number of small molecules that could
potentially interact with the ligand-binding pocket.
The commercially available top-scoring compounds were
screened for their ability to induce EphA2 activation in MDA-
MB-231 breast cancer cells. Because MDA-MB-231 cells express
endogenous EphA2 as well as other Eph receptors, including
EphA1, we overexpressed EphA2 (Figure S1) in order to minimize
the contribution from other Eph receptors in our analysis. The
cells were stimulated with the compounds at 50 mM. Total cell
lysates were probed with a previously described antibody that
recognizes the activated Eph receptors [27]. Figure 1C shows the
results from a representative subset of compounds with structures
given in Figure S2. Among the small molecules tested, compound
11, or doxazosin, activated EphA2 to the greatest extent.
Originally developed as an antagonist for a1-adrenoreceptor,
doxazosin (Figure 1D) is an FDA-approved drug (CarduraH)
commonly used clinically for treating hypertension and benign
prostate hyperplasia (BPH). To confirm specific EphA2 activation
by doxazosin, we analyzed levels of activated Eph receptor in
MDA-231-A2 cells following treatment with multiple doses of
doxazosin and EphA2 immunoprecipitation. Doxazosin activated
EphA2 receptor in a dose-dependent manner. Activation was
detectable at 25 mM and became stronger at 50 mM or higher
(Figure 1E). Similar to the native ligands, there was also
degradation of EphA2 following exposure to high doses of
doxazosin, which is characteristic of most RTKs upon ligand-
induced activation including Ephs [42].
Doxazosin induces catalytic activation of EphA2
independent of a1-adrenoreceptor antagonism
Because doxazosin is a well-characterized antagonist of a1-
adrenoreceptor, a question arose whether EphA2 catalytic
activation by doxazosin might be due to an indirect effect of its
a1-adrenoreceptor antagonism. To address this question, we
pretreated MDA-231-A2 cells with the well-characterized irre-
versible a1-adrenoreceptor inhibitor, phenoxybenzamine [28],
[29], [30], and then assayed for induction of EphA2 phosphor-
ylation by doxazosin. MDA-231-A2 cells were chosen because
they have previously been shown to express both a1a and a1b–
adrenoreceptors [31]. No difference in EphA2 activation by
doxazosin was observed following phenoxybenzamine pretreat-
ment versus no pretreatment (Figure 1F), demonstrating that
doxazosin directly activates EphA2 independent of its a1-
adrenoreceptor antagonism.
Two other top-scoring compounds, dobutamine and labetalol
(Compounds 9 and 10), function as a b1-adrenoreceptor agonist
and an a/b-adrenoreceptor antagonist, respectively. Treatment
with dobutamine failed to activate EphA2 up to 500 mM, while
labetalol failed to activate even at 500 mM, confirming that
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Figure 1. In silico screening identifies doxazosin as a novel agonist for EphA2 receptor. (A) Schematic illustration of the predicted effects
of small molecule agonists in inducing ligand-dependent signaling. (B) Crystal structure of the EphA2 ligand binding domain (LBD) in complex with
ephrin-A1. Highlighted are the hydrophobic pocket and arginine 103 of the EphA2-LBD that interact with the G–H loop of ephrin-A1 and glutamate
119 of ephrin-A1, respectively. EphA2-LBD was rotated ,10u counter-clockwise to better reveal the binding pocket. (C) Small molecule screening
identifies doxazosin (Compound 11) as a novel EphA2 agonist. MDA-231-A2 cells were treated with Compounds 1–11 (50 mM in 0.2% DMSO) for
30 minutes and cell lysates were subject to immunoblot for phosphorylated EphA/B kinases (pEphA/B) and total EphA2. (D) Chemical structure of
doxazosin (DZ). (E) Dose-response of EphA2 activation by DZ. MDA-231-A2 cells were treated with the indicated doses of DZ for 30 minutes and
lysates were immunoprecipitated with an EphA2-specific antibody and blotted as in (C). Treatment with 1 mg/ml ephrin-A1-Fc (EA1-Fc) for
10 minutes served as a positive control. Note decreasing amount of EphA2 following ephrin-A1 and doxazosin treatment. (F) Immunoblots for
pEphA/B on lysates from MDA-231-A2 cells pretreated with 1 mM phenoxybenzamine and then treated for 1 hour with indicated doses of DZ.
Treatment with 1 mg/ml ephrin-A1-Fc (EA1-Fc) served as a positive control. Treatment with 0.2% DMSO for either 1 hour (left), or 5 hours (right)
served as vehicle controls. (G) Representative plot from Surface Plasmon Resonance (SPR) analysis of DZ binding to the recombinant ligand binding
domain of EphA2. Curves from bottom to top represent concentrations of 1.56, 3.13, 6.25, 12.5, 25, 50 mM. Determined KD value is shown within plot.
(H) Molecular modeling of surface area diagram indicating amino acids of EphA2 potentially involved in direct interaction with doxazosin. The four
amino acids of the ephrin-A1 loop are shown in red. Images were created using UCSF Chimera.
doi:10.1371/journal.pone.0042120.g001
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doxazosin is indeed more potent and that activation is not a direct
result of general adrenoreceptor binding (Figure S3A).
Doxazosin directly interacts with the EphA2 LBD
Because doxazosin was discovered via virtual screening target-
ing the ligand binding pocket of EphA2, it was expected to directly
bind to the domain. To test this, binding of doxazosin to the
previously described recombinant LBD of EphA2 [24] was
analyzed using Surface Plasmon Resonance (SPR). We found that
doxazosin directly bound to the EphA2 LBD with a dissociation
constant (KD) of 47.6 mM (Figure 1G). Binding of both dobuta-
mine and labetalol was also tested and shown to occur with much
lower affinity than doxazosin (KD = 1.5 mM and 0.44 mM,
respectively) (Figure S3B). Taken together, these results demon-
strate that doxazosin directly binds to the EphA2 LBD.
Upon the recent determination of the X-ray crystal structure of
the EphA2-LBD in complex with ephrin-A1 [24], we compared it
with the homology model of EphA2 [23] used in the original
screening. Despite some expected differences, the EphA2 binding
site of the homology model was overall similar to the one in the
crystal structure (Figure S4), supporting general validity of the
molecular model for the virtual screening. Next, we repeated the
docking of doxazosin into the ligand binding site from the EphA2
crystal structure. Figure 1H shows doxazosin docked into the
EphA2 crystal structure, in an orientation similar to that in the
NMR structure of the EphA2-doxazosin complex (below). A new
round of virtual screening was also conducted using the EphA2
LBD crystal structure. However, of the 30 new top-scoring
compounds tested, we did not find agonists that displayed better
activities than doxazosin (not shown).
Doxazosin activates EphA2 receptor in different cell types
To determine whether the EphA2 agonist activity of doxazosin
is cell-context specific, we evaluated the effects of doxazosin on
additional cell types. We first utilized HEK 293 cells overexpress-
ing EphA2 (HEK 293-A2) that we described previously [9]. HEK
293 cells express low levels of endogenous EphA receptors [12];
overexpression of EphA2 in these cells allows further demonstra-
tion of specific activation of the exogenous kinase. Similar to
MDA-231-A2 cells, significant activation of EphA2 was seen in
HEK 293-A2 cells upon treatment with doxazosin starting at
25 mM (Figure 2A). Next we tested PC-3 cells that express high
levels of endogenous EphA2 receptor [32]. Doxazosin also
activated endogenous EphA2 in PC-3 cells, although it was not
evident until 50 mM. The different kinetics among these cell types
may be due, in part, to the different expression levels of EphA2 in
the three different cell lines or the specific cellular context. In
addition, EphA2 activation in PC-3 cells further supports the a1-
adrenoreceptor-independent mechanism, as these cells lack
detectable a1a-adrenoreceptor expression [33].
We next evaluated the time-course of activation in both MDA-
231-A2 and HEK 293-A2 cells upon treatment with a single
50 mM dose of doxazosin. Significant EphA2 activation could be
detected as early as 5 min after treatment in the MDA-231-A2 cell
line, which peaked around 30 min (Figure 2B). EphA2 activation
also became evident after 10 min treatment with doxazosin in
HEK 293-A2 cells, although it followed a slower kinetics.
Doxazosin preferentially activates EphA2 and EphA4
kinases
There are 14 mammalian Eph receptors that share significant
sequence homology [34]. This led us to investigate whether
doxazosin may also activate other Eph receptors. For this purpose,
HEK 293 cell lines overexpressing EphA1, EphA2, EphA3,
EphA4, and EphB3 kinases were utilized. We found that
doxazosin activated both EphA2 and EphA4 kinases following a
similar dose-response relationship (Figure 2C). However, no
activation of EphA1 was seen at the same concentrations, and
activation of EphA3 was weak compared to that of EphA2 and
EphA4. EphB3 has higher basal levels of activation (Figure 2C),
which was not further activated. In fact, there was a notable
decrease in EphB3 activation upon doxazosin exposure. There is
also a moderate level of endogenous EphB4 expression in HEK
293 cells; the lack of activated Eph kinase signals following
doxazosin exposure in vector control cells indicated that the
endogenous EphB4 was not activated either (Figure 2C). This data
shows that doxazosin preferentially activates EphA2 and EphA4
among the various Eph receptors tested.
NMR structure reveals extensive direct interactions of
doxazosin with EphA4
The dual selectivity of doxazosin for EphA2 and EphA4 opened
up a possibility to investigate the structural basis of the interactions
using NMR spectroscopy. Because the EphA2 LBD expressed in
E. coli was completely insoluble and could not be refolded after
repeated attempts, we focused on the interactions of the EphA4
LBD with doxazosin. First, we assessed EphA4 binding to
doxazosin by isothermal calorimetry. The dissociation constant
(KD) was calculated to be 12.4 mM (Figure S5A), similar to that of
EphA2/doxazosin interactions measured by SPR (Figure 1G).
Far-UV circular dichroism showed that doxazosin binding induces
no significant secondary structure change in the EphA4 LBD
(Figure S5B).
To characterize the binding interface, we acquired a series of
1H-15N heteronuclear single quantum coherence (HSQC) spectra
of the EphA4 LBD upon adding doxazosin at different molar
ratios. A gradual addition of doxazosin resulted in progressive
shifts of a subset of HSQC peaks (Figure 3A), consistent with the
relatively low affinity interaction. Most of these HSQC peaks did
not exhibit further shifts at molar ratios beyond 1:5. Therefore, the
chemical shift index (CSI) at this ratio was calculated (Figure 3B).
Upon binding to doxazosin, multiple clusters of residues under-
went dramatic shifts. While some of the shifts overlap with the
previously described C1 antagonists of EphA4 [35], many of the
shifts were unique to doxazosin (Figure 3B). The additional shifts
are distributed over the convex surface of the ephrin-binding
channel, including Val72-Cys73-Asn74 on E-strand, Thr104-
Leu105-Arg106 on G-strand, Leu166 on K-strand and Ile192-
Ala193 on M-strand. The larger contact area may account for the
higher affinity of doxazosin for EphA4 than that of C1.
To visualize the EphA4-doxazosin interaction interface, we
constructed models of the EphA4-doxazosin complex with the
HADDOCK software in combination with CNS, as described
previously for the EphA4-C1 complex [35]. The five lowest energy
models are shown in Figures S5C and S5D. Doxazosin has
extensive interactions with the EphA4 residues on the D–E and J–
K loops, as well as contacts with the convex b-strands composed of
Val72-Cys73-Asn74, Thr104-Leu105-Arg106 and Ile192-Ala193
(Figure 3C,D). Figure 3E highlights the interactions between the
two doxazosin methoxy groups and EphA4 hydrophobic residues
Met60 and Ile159. Interestingly, EphA4 has an additional binding
pocket characterized by a positively-charged Arg106 that
surrounds the electronegative oxygen atoms in benzodioxin and
carbonyl groups on doxazosin (Figure 3D,E,F). Together the
structural studies demonstrate direct interactions between EphA4
and doxazosin, and the KD is in similar concentration range
required for cellular activation of the receptor (Figure 2).
Discovery of an EphA2 Receptor Agonist
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Binding to doxazosin stabilizes the backbone of the
EphA4 LBD
Recent evidence shows that protein dynamics beyond the static
structure play an important role in various biological processes
including signal transmission [36], [37], [38], [39]. To gain
structural insight on how doxazosin may function as an EphA2
agonist, we characterized the backbone dynamics of the EphA4
LBD in the free state vs. that in complex with doxazosin (see
Methods S1). Briefly, we measured the backbone 15N relaxation
data T1, T2 and heteronuclear NOE values, which were then
analyzed by ‘‘Model-free’’ formulism [40], [41], [42]. The analysis
generated ‘‘squared generalized order parameters’’, S2, which
reflect the backbone rigidity on the ps-ns time scale. Figure S6A
demonstrates increased S2 values for a larger number of residues
upon EphA4 binding to doxazosin compared with free EphA4.
Many of the residues with significantly higher S2 values were
mapped to the backbone of EphA4 (Figure 3G). This observation
indicates that doxazosin stabilized the backbone of the EphA4
LBD on the ps-ns time scale.
Further evidence supporting the stabilization of the EphA4
LBD by doxazosin came from the chemical exchange rate, Rex,
that reflects the conformational changes on the ms-ms time scale of
individual residues. As shown in Figure S6B, many residues across
the EphA4 LBD in the free state exhibited significant Rex values,
indicating that they undergo extensive conformational changes. By
contrast, binding to doxazosin significantly reduced Rex values for
most residues, except for Asn74-Val75 and Thr121. The changes
in Rex values were then mapped back to the EphA4 structure
(Figure 3H), demonstrating dramatic decreases in conformational
changes in the doxazosin-bound vs. free state. In aggregate, our
structural analysis and protein dynamics modeling demonstrate
that doxazosin causes significant stabilization of the EphA4 LBD,
which may contribute to the agonistic functions of doxazosin.
A new model for the EphA2-doxazosin complex predicts
additional agonists
Next, we modeled EphA2-doxazosin interactions incorporating
the constraints from the EphA4-doxazosin structure. Sequence
and structural alignments revealed residues conserved between
EphA2 and EphA4 LBDs that showed significant peak shifts in
EphA4 upon binding to doxazosin. These correspond to Ile58,
Met59, Val69, Cys70, Asn71, Thr101, Val102, Arg103, Arg159,
Leu163, Val189 and Ala190 of EphA2. Figure 3I illustrates the
structure of the EphA2-doxazosin complex built with the
HADDOCK software. Similar to the EphA4-doxazosin complex,
the methoxy groups of doxazosin interact with the hydrophobic
surface formed by Ile58, Met59 and Ala158, while Arg103 of
EphA2 interacts with the carbonyl group and the oxygen atoms of
the benzodioxin part of doxazosin (Figure 3I). In addition, the
benzyl ring of the benzodioxin sits in a hydrophobic cavity of
EphA2 mainly constituted by Cys70, Thr101 and Ala190 side
chains (Figure 3I). Remarkably, in the recently determined X-ray
co-crystal structure of the EphA2-ephrin-A1 complex [24], ephrin-
A1 also interacts with the hydrophobic pocket and Arg103 of
EphA2 (Figure 1B), suggesting that doxazosin can recapitulate two
distinct modes of receptor interactions by the native ligand.
Doxazosin triggers EphA2-dependent inhibition of ERK
and Akt kinase activities
Activation of EphA2 receptor by ephrin-A1 ligand inhibits both
ERK1/2 and Akt kinase activities in most normal cells and a
subset of cancer cells [9], [12], [43]. Having demonstrated that
doxazosin could mimic ephrin-A1 in binding to and activating
EphA2 receptor, we asked whether doxazosin treatment could
inhibit ERK1/2 and Akt activation as well. We first tested this by
utilizing the A172 glioma cells engineered to overexpress EphA2
receptor (A172-A2). Unlike MDA-MB-231 cells that have
Figure 2. Doxazosin activates EphA2 receptor in different cell types. (A) Immunoblots for pEphA/B on lysates from PC-3 and HEK 293-A2
(293-A2) cell lines treated for 30 minutes with indicated doses of doxazosin (DZ). (B) Immunoblots for pEphA/B on lysates from MDA-231-A2 (231-A2)
and 293-A2 cell lines treated with 50 mM DZ in 0.2% DMSO for indicated times. (C) Doxazosin selectively activates EphA2 and EphA4 receptors.
Immunoblots for pEphA/B on lysates from HEK 293 cell lines expressing given Eph receptors following treatment with indicated doses of doxazosin
(DZ) for 60 minutes. Treatment with 1 mg/ml ephrin-A1-Fc ligand (EA1-Fc) for 10 minutes (EphA2) and 30 minutes (Vector, EphA1, EphA4), as well as
30 minute treatment with ephrin-A5-Fc (EA5-Fc) (EphA3) and ephrin-B1-Fc (EB1-Fc) (EphB3) served as positive controls. Blotting for total Eph kinases
served as loading controls.
doi:10.1371/journal.pone.0042120.g002
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activated Ras and are resistant to ephrin-A1-Fc induced inhibition
of ERK1/2, A172 cells harbor wild type Ras and exhibit high
basal activation levels of ERK1/2 and Akt, which were sensitive to
ephrin-A1-induced inhibition (Figure 4A, far fight lane). Similar to
other cell types tested (Figures 1 and 2), doxazosin also activated
EphA2 on A172 glioma cells in a dose-dependent manner starting
around 25 mM (Figure 4A). Moreover, treatment with 50 mM and
100 mM doxazosin was sufficient to cause significant inhibition of
Akt and ERK1/2 activation. The effects on Akt inhibition
coincided with EphA2 activation in these cells, and a higher
concentration was needed for ERK1/2 inhibition (Figure 4A).
Similar to MDA-231-A2 cells (Figure 1E), we observed degrada-
tion of EphA2 following doxazosin treatment in A172 cells.
Figure 3. Structure and dynamics of the EphA4-doxazosin complex. (A) 1H-15N NMR HSQC spectra of the EphA4 LBD in the absence (blue)
and in the presence (red) of doxazosin (DZ) at a molar ratio of 1:5 (EphA4:DZ). Several residues located over the convex surface of the EphA4 ephrin-
binding channel are labeled. (B) Residue-specific chemical shift index (CSI) of the EphA4 LBD in the presence of doxazosin at a molar ratio of 1:5
(EphA4:DZ). Significantly-shifted residues shared with C1 are colored in bright brown, while the residues significantly shifted only by doxazosin
binding are in red. (C) The docking model of the EphA4-doxazosin complex in ribbon. Binding regions identical to those for the C1-binding were
colored in brown, while those unique for the doxazosin binding in red. G, K, M and E are used to donate b-strands of the convex surface of EphA4/
ephrin-binding channel. (D) EphA4 residues having direct contacts with doxazosin. Residues on D–E and J–K loops are in brown, those on the convex
surface in violet, and Arg106 in cyan. Green dashed lines indicate hydrogen bonds between doxazosin and EphA4 residues. (E)–(F) The same docking
model with the electrostatic potential of the EphA4 LBD displayed. (G) EphA4 LBD in free and doxazosin-bound states display different squared
generalized order parameter S2 (Figure S6A). Blue: S2 difference #20.01; red: S2 difference $0.01; brown: no significant change or S2 values not
determined. (H) Conformational exchanges of EphA4 in free (left panel) and doxazosin-bound states (right panel). Residues with Rex.5 (Figure S6B)
are displayed in balls and colored in red. (I) A docking model of the EphA2-doxazosin complex. Contact residues in D–E and J–K loops are labeled in
brown, on the convex surface in cyan, and Arg103 in violet. The violet dash is used to indicate the hydrogen bonds between doxazosin and EphA2
residues.
doi:10.1371/journal.pone.0042120.g003
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While the results above showed that doxazosin treatment could
suppress Akt and ERK activation, a key question remained
whether this effect results specifically from EphA2 activation. To
address this question, we utilized an immortalized liver epithelial
cell line, LK133A, isolated from a hepatoma induced by DEN in
EphA2 knockout mice. Retroviral vector was used to restore
EphA2 expression in these cells (LK133A-A2), and cells
transduced with an empty vector were used as control (LK133A-
Vec). Figure 4B shows that, in the absence of EphA2, neither
doxazosin nor ephrin-A1-Fc was able to inhibit ERK and Akt
activities in LK133A-Vec cells (Figure 4B). In fact, there was a
notable increase in ERK and Akt activation by doxazosin.
Reintroduction of EphA2 expression restored ERK and Akt
inhibition not only by ephrin-A1-Fc but also by doxazosin, which
was accompanied by EphA2 activation. Similar to our findings in
A172-A2 cells, doxazosin inhibited Akt more strongly than
ERK1/2 and at a lower dose of doxazosin, again suggesting
differential inhibition of these pathways by EphA2. Together,
these data demonstrate that the inhibition of Akt and ERK1/2 by
doxazosin is dependent on EphA2, and doxazosin is capable of
triggering important downstream signaling events in a similar
fashion as the native ligand, ephrin-A1.
Doxazosin stimulates EphA2 receptor internalization and
causes cell rounding similar to ephrin-A1
Similar to other receptor tyrosine kinases, activation of the
EphA2 receptor by its ligand, ephrin-A1, results in receptor
internalization and eventual degradation [44]. The decreased total
level of EphA2 following doxazosin treatment in MDA-231-A2
cells (Figure 1E), A172 cells (Figure 4A), and EphA2 KO cells with
restored expression (Figure 4B) suggests that the receptor is also
being internalized and degraded. To directly demonstrate this at
the cellular level, we used immunofluorescence to monitor
localization of EphA2 following doxazosin treatment. This was
first performed using the U373 glioma cell line engineered to
overexpress EphA2. This cell line spreads well in culture, thereby
facilitating immunofluorescence detection of cell surface and
intracellular EphA2 [9]. Ephrin-A1-Fc was used as a positive
control, which induced nearly complete internalization of EphA2
within 60 min (Figure 5A). Consistent with its agonistic activities,
doxazosin also stimulated significant EphA2 internalization
(Figure 5A). We further tested EphA2 internalization by doxazosin
in parental MDA-MB-231 cells, and found that two hours of
treatment with 50 mM doxazosin caused significant internalization
of the endogenous EphA2, as well (Figure 5B). Together, these
data confirm that doxazosin indeed triggers EphA2 receptor
internalization in keeping with its agonistic activities.
As we first reported in 2000, EphA2 activation on PC-3 cells by
ephrin-A1 induced rapid cell rounding, a phenomenon that is
correlated with inhibition of integrin function [32]. To investigate
if doxazosin could also recapitulate this aspect of native ligand
function, PC-3 cells were stimulated with 50 mM doxazosin and
monitored for morphological changes. We found doxazosin also
caused rounding of PC-3 cells, which was similar to ephrin-A1,
albeit with a slower kinetics (Figure 5C).
Doxazosin inhibits haptotactic and chemotactic
migration of multiple cancer cell types
One of the well-established functions of Eph receptors is the
ligand-dependent repulsive guidance of cell migration [17]. As a
ligand-mimicking agonist for EphA2, doxazosin is expected to
activate EphA2 on tumor cells and repulse migrating tumor cells in
vitro. To test this possibility, we first investigated the effects of
doxazosin on integrin-mediated haptotactic cell migration toward
fibronectin in a modified Boyden chamber cell migration assay. As
shown in Figure 6, a dose-dependent inhibition of cell migration
was observed in MDA-MB-231 breast cancer cells (Figure 6A),
A172-A2 glioma cells (Figure 6B), as well as PC-3 prostate cancer
cells that were rendered highly migratory and metastatic via
DAB2IP knockdown [45], [46] (PC3-DAB2IP KD, see below)
(Figure 6C). The inhibitory effects were observed when doxazosin
was presented either in the bottom chamber, or in both top and
bottom chambers in the Transwell assay system. Next, we
examined chemotactic cell migration toward hepatocyte growth
factor (HGF) and found dose-dependent inhibition by doxazosin in
all three cell lines as well (Figure S7), albeit to a lesser degree than
those observed in the haptotactic migration assay. Therefore,
doxazosin can recapitulate a key function attributed to its native
ligands, i.e., negative regulation of cell migration.
Figure 4. Doxazosin inhibits activation of ERK1/2 and Akt in an EphA2-dependent manner. (A) Immunoblot of lysates from A172-A2 cells
treated with indicated doses of doxazosin (DZ) in 0.2% DMSO for 90 minutes. Treatment with 1 mg/ml ephrin-A1-Fc ligand for 10 minutes served as a
positive control. Lysates were immunoprecipitated with ephrin-A1-Fc (IP: EA1-Fc) as given in Methods, and probed for pEphA/B and total EphA2.
Total cell lysates were probed for phosphorylated forms of ERK1/2 and Akt, as well as total ERK1/2 and Akt. (B) Immunoblot of total cell lysates from
LK133A-Vec and LK133A-A2 cells treated with indicated doses of doxazosin (DZ) in 0.2% DMSO for 90 minutes. Treatment with 1 mg/ml ephrin-A1-Fc
for 10 minutes served as a positive control. Lysates were probed for phosphorylated forms of EphA/B, Akt, and ERK1/2, as well as total EphA2, Akt,
and ERK1/2.
doi:10.1371/journal.pone.0042120.g004
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Systemic administration of doxazosin suppresses distal
metastasis of prostate cancer in vivo
As tumor cell migration is involved at multiple steps leading to
distal tumor metastasis, the potent inhibition of cell migration by
doxazosin prompted us to examine whether it could have anti-
metastatic efficacy in vivo. Historically, studies of prostate cancer
metastasis in the preclinical setting have been hampered by the
lack of human cell lines that can produce significant metastasis in a
reproducible manner [47]. It was recently reported that knock-
down of DAB2IP, a known prostate tumor suppressor gene that is
often lost in aggressive prostate cancer patients, confers PC-3 cells
highly migratory and metastatic properties in vitro and in vivo [45],
[46]. We took advantage of this newly established model system to
test how doxazosin can affect metastasis of prostate cancer. To this
end, PC3-DAB2IP KD cells were injected orthotopically into the
prostate glands of nude mice. Three days later, recipient mice
were subject to systemic treatment by daily i.p. injection of either
vehicle control, or 50 mg/kg doxazosin for 10 days. Since these
cells also expressed green fluorescent protein (GFP), freshly
dissected primary tumors could be readily visualized in a GFP
light box (Figure 7A top panels), and distal metastases to lungs and
lymph nodes could be observed and quantified under a fluorescent
microscope (Figure 7A lower panels).
Remarkably, doxazosin treatment caused a significant reduction
in the number of lung metastases compared to vehicle control
(Figure 7A,B). The sizes of lung metastases were also significantly
smaller in doxazosin-treated mice than those from vehicle-treated
mice (Figure 7C). Total metastatic burden, taking into account
both numbers and sizes of metastases, was even more significantly
reduced in doxazosin-treated mice (Figure 7D). Tumor cell
dissemination to local lymph nodes was also reduced, but not to
a significant extent. Consistent with earlier reports [33], [48],
doxazosin-treated mice showed no notable side effects; there were
no changes in body weight compared with vehicle control
(Figure 7E), nor were there any signs of behavioral abnormalities,
suggesting a lack of general toxicity at the dose used. Doxazosin
has been previously shown to moderately decrease subcutaneous
growth of DU145 and PC-3 cell xenografts independent of a1-
adrenoreceptor [33], [49]. However, the direct target of doxazosin
was not identified in those studies. A reduction in primary tumor
sizes was also observed in doxazosin-treated mice, although the
difference was not statistically significant (not shown), suggesting
Figure 5. Doxazosin treatment causes EphA2 receptor internalization and induces cell rounding. (A) Immunofluorescence staining of
U373-A2 cells for EphA2 receptor (red) after treatment for 60 minutes with 50 mM DZ in 0.2% DMSO. Treatment with 1 mg/ml ephrin-A1-Fc and DMSO
served as positive and negative controls, respectively. DAPI nuclear staining is shown in blue. (B) Immunofluorescence staining of MDA-MB-231 cells
for EphA2 receptor (red) after treatment for 120 minutes with 50 mM DZ in 0.2% DMSO. Controls are as given above. Scale bars, 25 mm. (C) Images
from cell rounding analysis of PC-3 cells stimulated with 50 mM doxazosin for 30 or 60 min. Stimulation with 2 mg/ml ephrin-A1-Fc for 10 min or 0.2%
DMSO served as positive and negative controls, respectively. Cells were seeded on 6-well plates and stimulated after 24 hours.
doi:10.1371/journal.pone.0042120.g005
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that the dramatically reduced metastasis was unlikely due to the
smaller sizes of primary tumors.
Next, we determined whether doxazosin treatment might
impact overall survival. Nude mice orthotopically implanted with
the PC3-DAP2IP KD cells were treated for 10 days with either
doxazosin, or vehicle control and monitored for survival.
Consistent with earlier reports, the mice became moribund
starting around three weeks after cell implantation [45], [46].
The Kaplan-Meier plot revealed an increase in overall survival of
mice treated with doxazosin (70%) compared with vehicle-treated
mice (30%) at 27 days after cell implantation (Figure 7F). Taken
together, these preclinical data demonstrate that doxazosin can
inhibit metastasis of aggressive prostate cancer from the primary
site and improve overall survival in vivo.
Discussion
Using structure-based in silico screening in combination with
cell-based assays, we report here the identification and character-
ization of doxazosin as a novel EphA2 agonist that is independent
of its a1-adrenoreceptor antagonist functions. Doxazosin directly
bound to the recombinant EphA2 LBD with mM affinity and
induced phosphorylation of EphA2 at similar doses in breast and
prostate cancer cells, as well as glioma and hepatoma cells. Similar
to native ligand ephrin-A1, doxazosin stimulation resulted in
EphA2 internalization and degradation. Doxazosin treatment also
inhibited both Akt and ERK1/2 kinase activities downstream of
EphA2 activation. Consistent with the well-established ligand-
dependent roles of Eph in negatively regulating cell motility,
doxazosin retarded tumor cell migration in vitro. Moreover, in a
newly established orthotopic prostate cancer metastasis model,
doxazosin significantly reduced distant metastases of prostate
cancer cells. We propose that, as a FDA-approved drug
(CarduraH), doxazosin represents an attractive compound that
can be now re-purposed for treatment of aggressive prostate
cancer and potentially other malignant diseases.
Most current drug discovery efforts targeting kinases are focused
on identifying small molecules that inhibit enzyme function [50].
In the case of receptor tyrosine kinases, virtually all current drug
development endeavors are devoted to inhibitors targeting the
ATP binding pocket. Such inhibitor-focused approaches are
certainly justified in lieu of the pro-oncogenic role for most RTKs
in tumors. However, the unique ligand-dependent tumor suppres-
sor functions may make development of EphA2 agonists, rather
Figure 6. Integrin-mediated cell migration toward fibronectin is suppressed by doxazosin in a dose-dependent manner. MDA-MB-
231 (A), A172-A2 (B), and PC3-DAB2IP KD (C) cells were subject to haptotactic cell migration toward fibronectin as described previously (see
Methods). Doxazosin at indicated concentrations was presented at the lower chamber of the Transwells. Cells were allowed to migrate toward
fibronectin for 4 hours. Data represent average numbers of migrating cells from 6 randomly selected fields. DMSO was used as vehicle control.
doi:10.1371/journal.pone.0042120.g006
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than antagonists, a fruitful strategy for targeted therapy of a variety
of solid tumors. Likewise, other kinases with intrinsic tumor
suppressor functions, such as LKB1 [51] and LATS2 [52], can
also be suitable targets for agonist development. The general lack
of kinase agonists is often attributed to the prevailing belief that
gain-of-function agonists are more difficult to develop than the
loss-of-function antagonists/inhibitors. In this study, we utilized
virtual screening coupled with cell-based assays to identify
doxazosin as a bona fide agonist for EphA2 targeting the ligand-
binding domain (LBD). Both approaches are widely utilized in
contemporary drug discovery and can either be readily adapted,
or developed, suggesting the feasibility to find agonists for other
RTKs, including other members of the Eph subfamily.
The anti-metastatic effects of doxazosin are in keeping with the
anti-migratory and anti-invasive properties of ligand activated
EphA2 [3], [27]. We believe that the effects are likely to be more
pronounced in tumors where the ligand-independent, pro-
oncogenic functions of EphA2 predominate as a result of Akt-
mediated phosphorylation of EphA2 on serine 897 [9]. The latter
scenarios can take place when ligand expression is lost or reduced
relative to the often overexpressed EphA2 [15], [20], [21].
Alternatively, in some cellular contexts, EphA2 can be catalytically
silenced by ephrin-As on the same cells through inhibitory cis
interactions [53], [54]. In both situations, provision of exogenous
agonists acting in trans could still activate EphA2, unleashing its
intrinsic tumor suppressor functions to inhibit tumor cell migration
Figure 7. Doxazosin inhibits distal metastasis of human prostate cancer cells from orthotopic xenograft and prolongs survival. (A)
Fluorescent images of prostate tumors and lung metastases resulting from GFP-tagged PC3-DAB2IP KD cells after 10 days of treatment with either
vehicle, or 50 mg/kg doxazosin. Tumors in the prostate gland were imaged in a GFP light box, while lung metastatic foci were visualized under an
inverted fluorescence microscope. (B) Graph comparing total number of metastatic lung foci in individual vehicle-treated (n = 7) and doxazosin-
treated (n = 8) mice. (C) Quantitative analyses of total number of metastatic lung foci from different size categories. Categories were based on foci
diameter measured in number of cells (small = 1–3 cells, medium=4–6 cells, large = 7–10 cells). (D) Comparison of total metastatic burden (number of
foci6foci diameter) in mice treated with vehicle control vs. those treated with doxazosin. (E) Graph comparing bodyweights of vehicle- and
doxazosin-treated mice. Bars represent mean bodyweights. Error bars represent the SEM. Experiment was repeated three times with similar results. (F)
Kaplan-Meier Plot showing prolonged survival in mice treated with doxazosin (n = 8) compared with those treated with vehicle control (n = 9). Mice
were injected with the PC3-DAB2IP KD cells and treated as in (A) and closely monitored for survival. Those that became moribund were sacrificed.
Similar results were obtained from three independent experiments.
doi:10.1371/journal.pone.0042120.g007
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and invasion. It is important to note that, due to the complexity of
in vivo settings, we cannot completely rule out the possibility that
doxazosin exerts its anti-metastatic functions by affecting targets
other than EphA2 or a1-adrenoreceptor.
Previous studies analyzing the crystal structure of Eph/ephrin
interactions have primarily involved EphB kinases [22], [55], [56],
[57]. A recent study determined the crystal structure of the ligand-
binding domain of EphA2 and its interaction with ephrin-A1 [24].
The structure indicates that only minor conformational changes
occur in EphA2 upon ephrin-A1 binding, suggesting that the
ephrin-binding pocket on EphA2 is formed prior to ligand
binding, consistent with the ‘‘lock and key’’ model. This is in
contrast to EphB kinases, in which significant conformational
changes in the ephrin-binding pocket occur following ligand
binding, as a result of ‘‘induced fit’’ [22], [55]. This difference in
binding modes contributes to the ability of ephrin-A ligands to
more readily bind to their EphA receptors with much higher
affinities. In addition, while the high affinity interactions with the
ligand-binding channel of EphA2 are primarily involved in ephrin-
A1 binding, a second low affinity binding site is involved in EphB-
ephrin-B multimerization and resulting signaling [22]. In keeping
with this notion, the dimeric form of ephrin-A1, and even
monomeric ephrin-A1, is capable of activating EphA2 receptors,
whereas multimerization of ephrin-B1 is necessary for EphB2
activation [21], [24]. Due to this enhanced binding and activation,
it is suggested that EphA receptors represent better targets for
small molecules than EphB receptors. Indeed, no small molecules
targeting EphB receptors have yet been discovered.
Although doxazosin was discovered by virtual screening based
on the EphA2 structure, it can activate EphA4 kinase at similar
doses, but none of the other Eph receptors tested. This EphA2/
EphA4 dual specificity has been seen previously with small
molecule antagonists, which inhibited ephrin-A1 binding to both
EphA2 and EphA4 kinases at high mM concentrations [58]. This
shared specificity suggests structural similarities between EphA2
and EphA4 in the residues necessary for interaction with
doxazosin. Given the very promiscuous nature of EphA4, which
cross reacts with both ephrin-A and ephrin-B, this result is not
completely surprising. While the solubility problems prevented us
from directly determining the EphA2/doxazosin NMR structure,
we were able to model it based on the structure of EphA4/
doxazosin. The NMR structures revealed that doxazosin recapit-
ulates both hydrophobic and electrostatic interactions of ephrin-
A1 with EphA2 in the crystal structure, which could contribute to
its agonistic activities.
Interestingly, both doxazosin and C1 have similar binding
affinities and triggered no significant secondary structure changes
of the EphA4 LBD. However, doxazosin and C1 have opposite
functional effects. As revealed by the present NMR studies, in
addition to contacting with the EphA4 D–E and J–K loops,
doxazosin has extensive contacts with residues on the convex b-
strands of the ephrin binding pocket. These interactions are
observed in all complexes of Eph receptors bound to their natural
ephrin ligands, but are totally lacking in the EphA4-C1 complex.
This strongly suggests that designed molecules need to establish
interactions with residues on the J–K, D–E loops and the convex
b-strands to achieve agonistic activity. Further, the dynamic
stabilization on both ps-ns and ms-ms time scales upon doxazosin
binding might also play a crucial role in its agonistic activity.
Although challenging, further assessment of this phenomenon may
be performed by combining NMR spectroscopy and molecular
dynamic (MD) simulations as we recently conducted on another
system [38].
In summary, using structure-based virtual screening and cell-
based assays, we have identified and characterized doxazosin as a
novel small molecule agonist for EphA2. In addition, given both its
ability to inhibit prostate cancer growth and its ability to inhibit
prostate cancer metastasis, doxazosin may represent a cancer
therapeutic agent, particularly for aggressive prostate cancer.
Future optimization of the structure of doxazosin through
chemical derivatization may lead to the discovery of new EphA2
agonists with enhanced affinity, specificity, and potency for use as
more effective cancer therapeutics.
Materials and Methods
Cell lines and Reagents
Doxazosin, Labetalol, Dobutamine, and Phenoxybenzamine
were all purchased from Sigma. Other compounds from the
virtual screening high scoring list were obtained from Butt Park,
Ltd and Chembridge Corporation. Ephrin-A1-Fc, ephrin-B1-Fc,
ephrin-A5-Fc and rabbit anti-pEphA/B antibody were produced
as described previously [32], [57]. Sources of antibodies include
Santa Cruz Biotechnology (rabbit polyclonal anti-EphA2 and anti-
ERK1, mouse anti-pERK1/2), Cell Signaling Technologies (anti-
pS473-Akt and anti-Akt), R&D Systems (goat anti-EphA1, -
EphA3, -EphA4, -EphB3 antibodies) and Millipore [mouse
monoclonal EphA2 (clone D7)]. Rabbit polyclonal anti-EphB3
antibody was a gift from Dr. Elena Pasquale [27]. All cell lines
HEK 293, MDA-MB-231, A172 and PC-3 were purchased from
ATCC. PC-3-DAB2IP shRNA knockdown cells were established
and described [45], [46]. Cells were maintained in either
Dulbecco’s Modified Eagle Medium (DMEM), or RPMI 1640
(PC-3 and PC3-DAB2IP KD) supplemented with 10% FBS,
10 mg/ml glutamine, 100 U/ml penicillin, and 0.1 mg/ml
streptomycin.
In silico screening of compounds
For in silico screening we have used compounds from the NCI
database (,250000 compounds), Sigma database of rare chem-
icals (,100000 compounds) and Available Chemical Directory
(ACD) (http://mdl.com) (,350,000 commercially available). A
total of ,700,000 molecules were preprocessed before docking
using the FILTER utility from the OpenEye software package
(http://eyesopen.com) in order to eliminate toxic or reactive
chemicals and molecules without drug-like properties. This left
about 100,000 compounds for which multiple conformations were
generated using the OMEGA utility (OpenEye) for rigid docking.
The Gasteiger-Marsili atomic charges were assigned using BABEL
freeware utility. The 3D structure of the EphA2 receptor ligand
binding domain was obtained by homology modeling as described
previously [23].
The in silico screening was done using DOCK5.1 software.
DOCK5.1 implements a geometry-based approach for the
docking of the small ligands [59]. Connolly molecular surface
[60] of the EphA2 receptor structure was calculated using a probe
radius of 1.4 A˚. The negative image of the binding site was created
using the SPHGEN module, which generates the spheres of a
certain radii and calculates the best match of these spheres with
the molecular surface of the protein docking site. The DOCK
module was used to fit the small molecules from the database to
the centers of these spheres and the best obtained configurations
were scored in terms of energy using the AMBER force field [61].
The virtual screening was carried out on Beowulf cluster of Linux
machines at the Ohio Supercomputer Center.
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Surface Plasmon Resonance Analysis
Binding analysis was carried out using standard biosensor chips
and the SR7000DC Dual Channel SPR System (Reichert Life
Sciences, Depew, NY). The extracellular domain (ECD) of EphA2
was coupled to the chip by standard amine coupling using 1-ethyl-3-
(3-dimethylaminopropyl) carbodiimide (EDC) and N-hydroxysuc-
cinimide (NHS), followed by ethanolamine wash. In the case of
doxazosin, Neutravidin was coupled to the chip, followed by
ethanolamine wash and addition of minimally biotinylated EphA2
ECD to properly orient the protein. Different concentrations of
dobutamine, labetalol, and doxazosin in running buffer (PBS,
0.05% Tween-20, 1% DMSO) were flown over the chip at a rate of
75–90 ml/min and binding analyzed in real-time. After approxi-
mately 60 seconds, running buffer was flown over the chip to
dissociate the compounds from the coupled protein (downward
slope of curve). Binding data were analyzed and KD values
determined using Clamp software (BioLogic Software Pty Ltd).
Cell stimulation, immunoprecipitation, immunoblotting,
and immunofluorescence staining
Cells were plated in 24-well dishes at a density of 100,000 cells/
well and grown for 24 hours prior to stimulation with appropriate
compounds and ephrins for the given amounts of time.
Compounds were prepared in DMSO at 500 times the final
concentrations and 0.2% DMSO was used as vehicle control.
Following treatment, cells were lysed directly in SDS Gel Loading
Buffer and immunoblotted as described previously [32]. Immu-
noprecipitation and immunofluorescence staining was performed
as described [32]. For immunoprecipitation, 300,000 cells/well
were plated in 6-well dishes and lysed in modified RIPA Buffer
(20 mM Tris-HCl pH 7.4, 20 mM NaF, 150 mM NaCl, 10%
glycerol, 0.1% SDS, 0.5% DCA, 2 mM EDTA, 1% Triton X-100)
following treatment. Either 10 mg of ephrin-A1-Fc, or 4 mg of
EphA2 mouse monoclonal antibody (Clone D7, Millipore) were
used, and mouse IgG was used as a negative control for EphA2 IP.
ITC and NMR characterization of the binding of the
EphA4 LBD with doxazosin
Production of the 181-residue EphA4 ligand binding domain
(LBD, residues 29–209) and isothermal titration calorimetry (ITC)
experiments were performed as previously described [35]. To
characterize the binding of the EphA4 LBD and doxazosin by
NMR, two-dimensional 1H-15N HSQC spectra of the 15N-labeled
EphA4 LBD were acquired at 25uC with a protein concentration
of 100 mM in the absence and presence of Doxazosin at molar
ratios of 1:1; 1:2, 1:4, 1:5 and 1:6 (EphA4/DZ). By superimposing
HSQC spectra, the shifted HSQC peaks could be identified and
further assigned to the corresponding residues of the EphA4
ectodomain. The degree of perturbation was measured by an
integrated chemical shift index (CSI) calculated by the formula
[(DH)2+(DN)2/5]1/2 [35].
In vivo metastasis assay
PC-3 cells (from ATCC) engineered to express both GFP and
DAB2IP shRNA were characterized previously [46]. Cells were
suspended in serum free medium and 2,000 cells injected directly
into the prostate glands of 7 week old NCr athymic nu/nu mice.
Three days after injection, mice were divided into two groups, one
receiving vehicle alone (5% DMSO/10% Cremophor/PBS) and
another 50 mg/kg doxazosin via intraperitoneal injection daily for
10 days. Mice were sacrificed 14 days later and intact primary
tumors were imaged under a UV light box with a Digital camera.
Lungs were dissected into separate lobes and GFP-expressing
metastases were imaged using an inverted fluorescent microscope
(Leica). Metastases were enumerated in the two largest lung lobes
and placed into size categories based upon their diameters,
measured in number of cells (1–10 cells). Total metastatic burden
was calculated in each mouse using the following equation:
[burden =g(# of foci6focus diameter)].
All procedures involving mice were performed in accordance
with guidelines set forth by the American Association for
Accreditation of Laboratory Animal Care and the USPHS ‘‘Policy
on Humane Care and Use of Laboratory Animals’’. Studies were
approved and supervised by The Case Western Reserve University
Institutional Animal Care and Use Committee.
Statistical Analyses
Significance of results was determined using Student’s two-tailed
t-test. Differences were considered significant when P#0.05.
Supporting Information
Figure S1 MDA-231-EphA2 cells overexpress EphA2. Repre-
sentative immunoblot for activated Eph receptors (pEphA/B) and
total EphA2 on MDA-231-Vector and MDA-231-EphA2 cells
treated for given times with 1 mg/ml ephrin-A1-Fc ligand (EA1-
Fc). Blotting for total ERK served as a loading control.
(TIF)
Figure S2 Chemical structures of compounds screened for Eph
kinase activation.
(TIF)
Figure S3 EphA2 binding and receptor activation by dobuta-
mine and labetalol. (A) Immunoblots for pEphA/B on lysates from
MDA-231-A2 cells treated for 30 minutes with indicated doses of
dobutamine (DB) and labetalol (LB) in 0.2% DMSO. Blotting for
total EphA2 served as a loading control. Structures of DB and LB
are shown below respective blots. (B) Representative plots from
Surface Plasmon Resonance (SPR) analysis of DB and LB binding
to the recombinant extracellular domain (ECD) of EphA2 kinase.
Curves from bottom to top represent concentrations of 62.5, 125,
250, 500, 1000 mM. Determined KD values are shown within each
plot.
(TIF)
Figure S4 Comparison of the EphA2 ligand-binding domain
(LBD) homology model and crystal structure. Ribbon diagrams of
both the homology model (red) and crystal structure (yellow) of the
EphA2 LBD. Overlay of the homology model and crystal structure
is shown on the far right.
(TIF)
Figure S5 Biophysical characterization of the EphA4 and
doxazosin interaction. (A) ITC profile of the binding reaction of
the EphA4 LBD with doxazosin (top) and integrated values for
reaction heats with subtraction of the corresponding blank results
normalized by the amount of ligand injected vs the molar ratio of
EphA4/DZ (bottom). The thermodynamic binding parameters
obtained from fitting the data are shown in the box. (B) Far-UV
circular dichroism spectra of the EphA4 LBD in the absence (blue)
and in the presence of doxazosin (red) at a molar ratio of 1:5
(EphA4:DZ). (C)–(D) Superimposition of five lowest-energy
docking structures of the EphA4-doxazosin complex.
(TIF)
Figure S6 15N backbone dynamics of the free and doxazosin-
complexed EphA4 LBD. (A) Differences of the squared general-
ized order parameters (S2) between the EphA4-doxazosin complex
and free EphA4 LBD. The bars with positive values are colored in
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red while ones with negative values in blue. (B) Rex values derived
from the model-free analysis of the relaxation data. Data for the
free EphA4 LBD are colored in blue while those for the EphA4 in
complex with doxazosin are colored in red.
(TIF)
Figure S7 Inhibition of chemotactic cell migration of PC3-
DAB2IP KD, A172-A2, and SCP3-231 cells upon doxazosin
treatment. PC3-DAB2IP KD, A172-A2, and SCP3-231 cells were
subject to chemotactic cell migration toward 15 ng/ml hepatocyte
growth factor (HGF) as described previously (see Methods S1).
HGF and doxazosin at indicated concentrations were presented in
the lower chamber of the Transwells. Cells were allowed to
migrate toward HGF for 5 hours. Data represent average
numbers of migrating cells from 6 randomly selected fields.
DMSO was used as vehicle control.
(TIF)
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